ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Skin Diseases
Food Hypersensitivity
Hypersensitivity
Psoriasis
Allergic Rhinitis

Eczema trials near Hanyang, Seoul, KOR:

A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy (ADHAND)

The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. Th...

Enrolling
Atopic Hand Eczema
Atopic Dermatitis
Drug: Placebo
Drug: Tralokinumab

Phase 3

LEO Pharma
LEO Pharma

Seoul, Korea, Republic of and 73 other locations

This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or a...

Enrolling
Atopic Dermatitis
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

Phase 3

Incyte
Incyte

Seoul, Korea, Republic of and 103 other locations

This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK10...

Enrolling
Dermatitis, Atopic
Drug: GSK1070806
Drug: Placebo

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, Korea, Republic of and 95 other locations

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Phase 3

Pfizer
Pfizer

Seoul, Korea, Republic of and 558 other locations

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Phase 3

Lilly
Lilly

Seoul, Korea, Republic of and 320 other locations

Locations recently updated

assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 300 adult pa...

Enrolling
Atopic Dermatitis
Drug: Upadacitinib Dose B
Drug: Upadacitinib Dose A

Phase 3

AbbVie
AbbVie

Seoul, Seoul Teugbyeolsi, Korea, Republic of and 60 other locations

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants w...

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: Lebrikizumab

Phase 3

Lilly
Lilly

Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of and 46 other locations

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

Phase 3

Amgen
Amgen

Seoul, Korea, Republic of and 487 other locations

The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneous using devices for injection at home.

Enrolling
Atopic Dermatitis
Combination Product: Rocatinlimab AI
Combination Product: Rocatinlimab Prefilled Syringe

Phase 3

Amgen
Amgen

Seoul, Korea, Republic of and 44 other locations

A Multicenter, Randomized, Single-Blind, Phase Ⅱ Clinical Trial and Open Label Long-term Observation Study of ADSTEM Inj. to Evaluate the Safety and...

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Biological: ADSTEM Inj.

Phase 2

EHL Bio

Seoul, Seoulteukbyeolsi, Korea, Republic of and 5 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems